Literature DB >> 21385898

CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells.

Kai-Oliver Henrich1, Tobias Bauer, Johannes Schulte, Volker Ehemann, Hedwig Deubzer, Sina Gogolin, Daniel Muth, Matthias Fischer, Axel Benner, Rainer König, Manfred Schwab, Frank Westermann.   

Abstract

A distal portion of human chromosome 1p is often deleted in neuroblastomas and other cancers and it is generally assumed that this region harbors one or more tumor suppressor genes. In neuroblastoma, a 261 kb region at 1p36.3 that encompasses the smallest region of consistent deletion pinpoints the locus for calmodulin binding transcription activator 1 (CAMTA1). Low CAMTA1 expression is an independent predictor of poor outcome in multivariate survival analysis, but its potential functionality in neuroblastoma has not been explored. In this study, we used inducible cell models to analyze the impact of CAMTA1 on neuroblastoma biology. In neuroblastoma cells that expressed little endogenous CAMTA1, its ectopic expression slowed cell proliferation, increasing the relative proportion of cells in G(1)/G(0) phases of the cell cycle, inhibited anchorage-independent colony formation, and suppressed the growth of tumor xenografts. CAMTA1 also induced neurite-like processes and markers of neuronal differentiation in neuroblastoma cells. Further, retinoic acid and other differentiation- inducing stimuli upregulated CAMTA1 expression in neuroblastoma cells. Transciptome analysis revealed 683 genes regulated on CAMTA1 induction and gene ontology analysis identified genes consistent with CAMTA1-induced phenotypes, with a significant enrichment for genes involved in neuronal function and differentiation. Our findings define properties of CAMTA1 in growth suppression and neuronal differentiation that support its assignment as a 1p36 tumor suppressor gene in neuroblastoma. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385898     DOI: 10.1158/0008-5472.CAN-10-3014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 2.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

4.  Integrator of Stress Responses Calmodulin Binding Transcription Activator 1 (Camta1) Regulates miR-212/miR-132 Expression and Insulin Secretion.

Authors:  Inês Guerra Mollet; Helena Anna Malm; Anna Wendt; Marju Orho-Melander; Lena Eliasson
Journal:  J Biol Chem       Date:  2016-07-08       Impact factor: 5.157

5.  Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study.

Authors:  Jota Mikami; Yukinori Kurokawa; Tsuyoshi Takahashi; Yasuhiro Miyazaki; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2015-10-20       Impact factor: 7.370

6.  Ataxia and Purkinje cell degeneration in mice lacking the CAMTA1 transcription factor.

Authors:  Chengzu Long; Chad E Grueter; Kunhua Song; Song Qin; Xiaoxia Qi; Y Megan Kong; John M Shelton; James A Richardson; Chun-Li Zhang; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

7.  UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Authors:  Peter E Zage; Natalie Sirisaengtaksin; Yin Liu; Monica Gireud; Brandon S Brown; Shana Palla; Kristen N Richards; Dennis P M Hughes; Andrew J Bean
Journal:  Cancer       Date:  2012-09-18       Impact factor: 6.860

8.  Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein.

Authors:  M R Tanas; S Ma; F O Jadaan; C K Y Ng; B Weigelt; J S Reis-Filho; B P Rubin
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

9.  A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

Authors:  Siyuan Zheng; Jun Fu; Rahulsimham Vegesna; Yong Mao; Lindsey E Heathcock; Wandaliz Torres-Garcia; Ravesanker Ezhilarasan; Shuzhen Wang; Aaron McKenna; Lynda Chin; Cameron W Brennan; W K Alfred Yung; John N Weinstein; Kenneth D Aldape; Erik P Sulman; Ken Chen; Dimpy Koul; Roel G W Verhaak
Journal:  Genes Dev       Date:  2013-06-24       Impact factor: 11.361

10.  CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.

Authors:  Daniel Schraivogel; Lasse Weinmann; Dagmar Beier; Ghazaleh Tabatabai; Alexander Eichner; Jia Yun Zhu; Martina Anton; Michael Sixt; Michael Weller; Christoph P Beier; Gunter Meister
Journal:  EMBO J       Date:  2011-08-19       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.